Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
Top Breast Cancer Research at ASCO 2025
Top Breast Cancer Research at ASCO 2025
Dr. Eleonora Teplinsky explains DESTINY-Breast09, ASCENT-04, and SERENA-6.
Jun 2, 2025
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured five days of presentations and educational sessions on all types of cancer. Dr. Eleonora Teplinsky, a board-certified medical oncologist at the Valley-Mount Sinai Comprehensive Cancer Center in Paramus, NJ, summarizes the top breast cancer research.
Listen to the episode to hear Dr. Teplinsky discuss:
- The SERENA-6 trial, which found that if metastatic hormone receptor-positive, HER2-negative breast cancer develops ESR1 mutations during the first hormonal therapy treatment, switching to camizestrant from an aromatase inhibitor before the cancer grows improves outcomes.
- Results from the DESTINY-Breast09 trial showing that the combination of Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Perjeta (chemical name: pertuzumab) is a better first treatment for metastatic HER2-positive breast cancer than the current standard of THP chemo.
- The ASCENT-04/KEYNOTE-D19 trial, which found that people with metastatic PD-L1-positive, triple-negative breast cancer fared better with the combo of Trodelvy (chemical name: sacituzumab govitecan-hziy) and Keytruda (chemical name: pembrolizumab) as a first treatment compared to people who received chemotherapy and Keytruda.
Tagged:
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.